Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Pietro

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
World Journal of Gastroenterology|October 10, 2013
Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registryRehan J Haidry, Mohammed A Butt, Jason Dunn, et al.
BMC Medical Informatics and Decision Making|June 16, 2011
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimenMattia C F Prosperi, Simona Di Giambenedetto, Iuri Fanti, et al.
Antiviral Therapy|May 29, 2009
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in ItalySimona Di Giambenedetto, Maurizio Zazzi, Paola Corsi, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
Plos One|September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentGiuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2017
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, et al.
Frontiers in Immunology|March 1, 2019
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up StudyCecilia Sgadari, Paolo Monini, Antonella Tripiciano, et al.
Ebiomedicine|April 11, 2021
Anti-Tat immunity defines CD4<sup>+</sup> T-cell dynamics in people living with HIV on long-term cARTAntonella Tripiciano, Orietta Picconi, Sonia Moretti, et al.
Retrovirology|June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyStefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
World Journal of Gastroenterology|October 10, 2013
Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registryRehan J Haidry, Mohammed A Butt, Jason Dunn, et al.
BMC Medical Informatics and Decision Making|June 16, 2011
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimenMattia C F Prosperi, Simona Di Giambenedetto, Iuri Fanti, et al.
Antiviral Therapy|May 29, 2009
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in ItalySimona Di Giambenedetto, Maurizio Zazzi, Paola Corsi, et al.
Medicine|July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort studyEmanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
Plos One|September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentGiuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2017
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, et al.
Frontiers in Immunology|March 1, 2019
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up StudyCecilia Sgadari, Paolo Monini, Antonella Tripiciano, et al.
Ebiomedicine|April 11, 2021
Anti-Tat immunity defines CD4<sup>+</sup> T-cell dynamics in people living with HIV on long-term cARTAntonella Tripiciano, Orietta Picconi, Sonia Moretti, et al.
Retrovirology|June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyStefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
Pageof 6